Metro International Biotech is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD+ precursors in the world.
NAD+ levels have been shown to decline as humans age and increasing NAD+ to preserve health and normal metabolism is believed to have broad pharmaceutical potential. Metro International Biotech has assembled a team of industry-leading scientists to drive its lead compound, MIB-626, through clinical development and fuel the Company’s robust R&D engine, building a library of next-generation analogs with tissue-selective NAD+ increasing properties.
Our Mission:
To enable longer, healthier lives.
TEAM
Since its founding, Metro International Biotech has built a world class, highly collaborative team of leading NAD+ experts, with extensive clinical and corporate experience, as well as in related fields such as metabolic pathways, drug development and manufacturing, molecular biology, isotopic labeling and nucleoside chemistry.
MANAGEMENT
Edward Schulak, Chairman
David J. Livingston, MBA, Ph.D., President and Chief Scientific Officer
David B. Pryor, M.D., Chief Medical Officer
Bruce Szczepankiewicz, Ph.D., Vice President, Chemistry
Kevin B. Clairmont, Ph.D., Vice President, Biology
Scientific Advisory board
Rajendra Apte, M.D., Ph.D.
Johan Auwerx, M.D., Ph.D.
James Ellis, Ph.D.
Neil Flanzraich, JD.
Nick Lane, Ph.D.
Jeffrey Lieberman, M.D.
Li-Huei Tsai, Ph.D.
Lindsay Wu, Ph.D.
What We've Achieved
Manufacturing a naturally occurring proprietary human clinical grade NAD+ enhancer
Designed and synthesized over 100 novel NAD+ enhancers, screened for optimal therapeutic properties
Gathered robust preclinical data supporting the broad therapeutic potential of modulating NAD+
Developed solid oral dosage formulations of MIB-626, with scalable manufacturing capabilities
Protected extensive IP portfolio, with 21 patent families and in-house proprietary R&D
Ongoing Phase 2 trials at leading hospitals
